Diabetes Associated Ophthalmic Treatment Market Revenue to Attain USD 12.65 Bn by 2035

Published: 02 Mar 2026

Author: Precedence Research

Share:

Diabetes Associated Ophthalmic Treatment Market Revenue and Trends 2026 to 2035

The global diabetes associated ophthalmic treatment market revenue was valued at USD 6.91 billion in 2025 and is expected to attain around USD 12.65 billion by 2035, growing at a CAGR of 6.24% during forecast period.The market's growth is driven by several factors, including rising demand for minimally invasive ophthalmic surgeries and rapid advancements in anti-VEGF therapies.

What are the Factors Contributing to the Growth of the Diabetes Associated Ophthalmic Treatment Market?

The rising global prevalence of diabetes, mainly type-2, often leads to ophthalmic complications and other conditions, which is the major driver, accelerating the growth of the market. The market’s growth is also primarily supported by advancements in anti-VEGF therapies and the rising geriatric population. Elder individuals are more susceptible to diabetic eye complications, such as age-related retinal vascular diseases.

Segment Insights

• By disease type, the diabetic retinopathy segment held the largest market share in 2025, owing to the increasing efforts of key players to launch effective drugs for the treatment of diabetic retinopathy. Diabetic retinopathy is a serious medical condition that impacts the eyes of the patient, leading to vision loss. It often leads to severe blindness if ignored.
• By treatment type, the pharmaceuticals segment accounted for the majority of the market share in 2025, owing to the increasing adoption of anti-VEGF therapy. Pharmacological treatments are the first-line approach in managing diabetic macular edema (DME) and diabetic retinopathy (DR). 
• By route of administration, the intravitreal injection segment registered its dominance in the global market with the highest market share in 2025, owing to its ability to deliver high concentrations of anti-VEGF drugs directly to the retinal tissue.
• By end-user, the hospitals segment dominated the market with the largest market share in 2025, owing to the high volume of diabetes patient admissions. Hospitals have specialized infrastructure, trained retinal surgeons, and advanced diagnostic & surgical facilities. Hospitals are well equipped to handle the high volume of Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME) patients.
• By age group, the working-age adults segment contributed the biggest market share in 2025. This population represents the largest share of individuals living with diabetes around the world. Consistent high blood glucose levels during prime working years increase the risk of complications such as diabetic retinopathy and diabetic macular edema, driving the demand for advanced diagnosis and treatment.

Regional Insights

North America holds the dominant share in the global diabetes associated ophthalmic treatment market. The region’s leadership is driven by the strong presence of key pharmaceutical and biotechnology companies, sophisticated healthcare infrastructure, the increasing prevalence of diabetes and its related ocular complications, growing need for anti-VEGF injections, rising patient awareness, increasing adoption of AI-enabled eye detection facilities, and favorable reimbursement frameworks.

On the other hand, Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period. The fastest growth of the region is attributed to the rising investments in diagnostic infrastructure, a surge in R&D funding by pharma/biotechnological companies, and growing demand for Anti-VEGF therapy. In addition, the increasing patient population with diabetes related ocular complications, along with the increasing number of specialized eye care clinics, is expected to drive the market’s growth in the Asia Pacific region.

Diabetes Associated Ophthalmic Treatment Market Coverage

Recent Developments

• In February 2025, Roche announced that the U.S. Food and Drug Administration (FDA) had approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a leading cause of vision loss in adults with diabetes, affecting more than 29 million adults worldwide.1-3 Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than standard-of-care eye injections.(Source: https://www.roche.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7861

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344